Recombinant Human CEACAM6 /CD66c Protein
- Known as:
- Recombinant Human CEACAM6 /CD66c Protein
- Catalog number:
- ce-686
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human CEACAM6 /CD66c Protein
Related genes to: Recombinant Human CEACAM6 /CD66c Protein
- Gene:
- CEACAM6 NIH gene
- Name:
- carcinoembryonic antigen related cell adhesion molecule 6
- Previous symbol:
- NCA
- Synonyms:
- CD66c
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human CEACAM6 /CD66c Protein
Related articles to: Recombinant Human CEACAM6 /CD66c Protein
- In recent years, the concept of "modality" has attracted significant attention in drug discovery, encompassing diverse approaches such as small molecules, antibodies, nucleic acids, and cell-based therapies. Eisai has leveraged its long-standing expertise in small-molecule drug design to focus on proximity-inducing compound (PIC), which induces novel pharmacological effects by bringing two distinct proteins into close proximity. PIC form ternary complexes between a target protein and an effector protein, enabling mechanisms such as targeted degradation, post-translational modification, and modulation of protein-protein interactions. This strategy allows intervention in previously "undruggable" targets that lack suitable binding pockets for conventional inhibitors. Among PIC, targeted protein degraders such as proteolysis targeting chimera (PROTAC) and molecular glue degrader (MGD) have advanced rapidly into clinical development worldwide. Eisai's entry into this field was driven by the discovery of the unique mechanism of action of Indisulam and E7820, which function as MGD to degrade RBM39 via DCAF15 recruitment. Building on this foundation, Eisai is pursuing tumor-selective strategies, including the development of a CEACAM6-targeted degrader antibody conjugate (DAC) and PROTAC utilizing tumor-selective E3 ligases. These approaches aim to achieve both efficacy and safety by restricting degradation activity to cancer cells. PIC represent a transformative modality that expands the druggable proteome and offers new therapeutic options for intractable diseases. This article outlines Eisai's efforts in PIC-based drug discovery, with a focus on targeted protein degradation and future perspectives. - Source: PubMed
Kira Kazunobu - Gallbladder cancer (GBC) is a highly lethal disease which is usually diagnosed at advanced stage owing to unavailable screening tools and effective therapies. Persistent inflammation induced by various risk factors is the main cause of GBC, however, the molecular program remains elusive. Unveiling the molecular trajectory and events during gallbladder epithelium malignant transformation contribute to prevention and drug discovery for GBC. Single cell RNA sequencing was performed by using 4 gallbladder adenoma and cancer samples. Pseudotime trajectory analyses were employed to reconstruct epithelium transformation track in order to identify crucial genes which promoted GBC development. Functional and mechanism studies were performed to validate the regulatory network and cell behavior in vitro and in vivo. Three clusters of gallbladder epithelium were identified among GBC microenvironment which were characterized by distinct epithelial mesenchymal transition (EMT) and inflammation states. Cell adhesion molecular binding was the most significant GO term between EMT high and low states, in which OLFM4 was differentially expressed gene participated. Further studies implicated that OLFM4 could promote GBC metastasis and activate EMT through CEACAM6/AKT signaling cascade, and the CEACAM6 expression was regulated by TGF-β/Smad3 pathway. Interestingly, we disclosed that TGFβR1 was the functional receptor of OLFM4, through which the tumorigenic signaling of OLFM4 was transduced. These findings suggest the oncogenic role of OLFM4 during GBC carcinogenesis which can be a candidate biomarker of GBC, and OLFM4, TGFβR1 and downstream signaling elements are promising therapeutic targets for GBC. - Source: PubMed
Publication date: 2026/04/29
Yang SonglinHuang WenwenZeng QingjuWang XiaodanLin ShuchengMeng MingyaoWang LiqiongWang HuiWang RuotianLi LinChen XiaofangWei ZichunLin ZhuyingYe QiuwenLi RuhongTan JingWang Wenju - Invasive candidiasis is a fungal infection characterized by a high mortality rate. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family receptors play a crucial role in regulating innate responses of both leukocytes and epithelia. Human CEACAM3, CEACAM5 and CEACAM6 receptors recognize and are expressed in transgenic CEABAC10 mice. In a murine infection model, CEABAC10 mice exhibited a shortened survival period attributed to an early cytokine storm, an exacerbated acute phase response, and heightened systemic inflammation compared to their wild-type littermates. The livers and kidneys of CEABAC10 mice displayed intensified purulent necrotizing inflammation, accompanied by increased infiltration of neutrophils and macrophages. Our in vivo and in vitro data indicated that the expression of CEACAM6 on monocytes of CEABAC10 mice caused the elevated cytokine levels and the subsequent exacerbation of the acute phase response upon infection, resulting in decreased survival. - Source: PubMed
Publication date: 2026/04/16
Klaile EstherMüller Mario MarcoSonnberger JohannesBothe Anne-KatrinBrehme SaskiaEhrenpfordt JulietKlassert Tilman EikeKuhn SabinaDietert KristinaKershaw OliviaPraetorius Jan-PhilippFigge Marc ThiloBauer TorstenGebhardt AndreasMall GitaJacobsen Ilse DeniseSlevogt Hortense - Identifying viruses with zoonotic potential on the basis of their ability to enter human cells is a critical component of pandemic prediction, prevention and preparedness. Here using a computational approach that retains maximum phylogenetic diversity, we selected an optimal subset of alphacoronavirus spike proteins to screen against broad coronavirus receptor libraries. Most of the selected spike proteins did not use any of the established coronavirus receptors. However, the pseudotyped spike protein of Cardioderma cor (heart-nosed bat) coronavirus KY43 (CcCoV-KY43) could enter human cells. Using a recombinant CcCoV receptor-binding domain (RBD) and a human receptor screening platform, we identified direct interactions with the human CEACAM proteins CEACAM3, CEACAM5 and CEACAM6. Overexpression of human CEACAM6-a protein widely expressed in the human lung-conferred permissivity to otherwise refractory human cells. A crystal structure showed that the RBD binds the amino-terminal IgV-like domain of human CEACAM6. Immune surveillance studies using sera of individuals from the Taveta region of Kenya, where CcCoV-KY43 was identified, did not show significant evidence of recent spillover. Wider characterization of alphacoronaviruses related to CcCoV-KY43 showed that human CEACAM6 is used by two other CcCoVs collected in Kenya. Moreover, there was more restricted nonhuman CEACAM6 tropism for viruses isolated from Rhinolophus bats from Russia and China. Thus, alphacoronaviruses that use CEACAM6 are probably geographically widespread, and viruses from East Africa show potential for transmission to humans. - Source: PubMed
Publication date: 2026/04/22
Gallo GiuliaDi Nardo AntonelloLugano DoreenRoberts Adam JKutima Bernadette AtakuOkombo MosesDewantari Aghnianditya KresnoBuckley Florence M MWright Gavin JNyagwange JamesAgwanda BernardGraham Stephen CBailey Dalan - Biomarkers for colorectal cancer (CRC) measured in blood at various time-points represents potential tools for disease monitoring and additional staging complementing tissue-based diagnostics. Currently, the only marker in routine clinical use is carcinoembryonic antigen (CEA). Other carcinoembryonic antigen-related cell adhesion molecules (CEACAM) such as CEACAM1 and CEACAM6, have been implicated in tumour progression, however their serum levels in relation to clinical features remain insufficiently explored. - Source: PubMed
Publication date: 2026/04/22
Kanani ArezoAlexeeva MarinaVinod RufusPettersson KimLeivo JanneSøreide Kjetil